Trials explorer

AI-generated summary

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer is being studied. Conditions: BRAF V600 Colorectal Cancer • Eligibility: Inclusion Criteria: * Age ≥18 years and ≤75 years * Histologically confirmed metastatic colorectal adenocarcinoma * BRAF V600E mutation confirmed by tissue pathology or ctDNA testing (PCR or…. Goal: The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The main questions it aims to answer are: Does IB-FOLFIRI improve clinical outcomes compared with historical outcomes in this population? Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether adding cemiplimab to the standard drugs dabrafenib and trametinib helps adults with anaplastic thyroid cancer. - It is for people whose cancer has the BRAF-V600E mutation and is metastatic or not surgically curable, with measurable disease. - Researchers want to learn if this combination improves cancer control and patient outcomes. - Key exclusions include prior dabrafenib/trametinib treatment (with limited exceptions), active brain metastases, certain autoimmune conditions or infections, HIV on antiretroviral therapy, and other serious medical issues. - The study is currently not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG is being studied. Conditions: High Grade Glioma, BRAF V600E, BRAF V600K +4 • Eligibility: Inclusion Criteria: 1. Patients receiving any other standard or investigational agents are ineligible. 2. Patients with history or current evidence of the following conditions are excluded: neuromuscular disorder…. Goal: The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer is being studied. Conditions: BRAF V600E-mutated /MSS Metastatic Colorectal Cancer, Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody • Eligibility: Inclusion Criteria: 1. Male or female ≥ 18 years of age 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 3. Participants must have histologically or cytologically…. Goal: BRAF mutation exists in about 10-12% of colorectal cancer, among which BRAF V600E mutation is the most common type, which is an important biomarker for predicting the prognosis and precise treatment efficacy of metastatic colorectal cancer (mCRC). The prognosis of metastatic colorectal cancer with BRAF V600E mutation is very poor, with OS of about 6-9 months. Phase/Status/Sponsor: Unknown phase; UNKNOWN; West China Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria: 1. Has or is willing to give consent to the…. Goal: The purpose of this Cohort Treatment Plan is to allow access to trametinib (monotherapy or in combination) and dabrafenib (monotherapy or in combination) for eligible patients diagnosed with metastatic melanoma BRAF mutation-positive. Phase/Status/Sponsor: Unknown phase; NO_LONGER_AVAILABLE; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests amivantamab plus FOLFIRI versus cetuximab/bevacizumab plus FOLFIRI in people with KRAS/NRAS and BRAF wild-type colorectal cancer who have previously received chemotherapy. - It aims to learn whether the amivantamab combination improves progression-free survival and overall survival compared with the cetuximab/bevacizumab combination. - Eligible participants have recurrent, unresectable, or metastatic colorectal cancer with confirmed KRAS/NRAS and BRAF wild-type status, have had at least one prior systemic therapy for metastatic disease, and have ECOG 0–1. - Key exclusions include preexisting interstitial lung disease/pneumonitis, allergies to study drugs, prior exposure to irinotecan or EGFR/MET inhibitors, HER2-positive tumors, or another active malignancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery is being studied. Conditions: BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma +5 • Eligibility: Inclusion Criteria: * Study participants must have histologically or cytologically confirmed unresectable or metastatic malignant melanoma * Study participants must have measurable disease, defined as at least one…. Goal: This randomized phase I trial studies the side effects and best way to give ipilimumab with or without dabrafenib, trametinib and/or nivolumab in treating patients with melanoma that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Phase/Status/Sponsor: Unknown phase; TERMINATED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients is being studied. Conditions: Colorectal Cancer, Liver Metastases • Eligibility: Inclusion Criteria: * Age ≥18 and ≤75 years old * Histologically confirmed colorectal adenocarcinoma * Radiological and/or pathological confirmation of liver metastases, with ≤5 lesions * Genetic testing…. Goal: The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in the liver, increase T lymphocyte infiltration, and consequently improve the postoperative prognosis for patients with surgically resectable colorectal cancer liver metastases (RAS/BRAF wild-type, pMMR/MSS) compared to FOLFOX alone. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer is being studied. Conditions: Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 +2 • Eligibility: Inclusion Criteria: * PRE-REGISTRATION (STEP 0) ELIGIBILITY CRITERIA: * BRAF V600 mutational status may be determined either locally or by central testing. This testing is mandatory prior to…. Goal: This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Alliance for Clinical Trials in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis is being studied. Conditions: Malignant Melanoma • Eligibility: Inclusion Criteria: 1. Men and women ≥ 18 years of age. 2. Histologically confirmed metastatic cutaneous melanoma, mucous melanoma, or melanoma of unknown primary origin (stage IV). 3.…. Goal: The purpose of this study is to determine wether cobimetinib + vemurafenib combination treatment is effective in the treatment of BRAFV600-mutated melanoma patients with brain metastasis Phase/Status/Sponsor: Unknown phase; COMPLETED; Center Eugene Marquis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Adults \>= 18 years old * Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic) and determined to be BRAF…. Goal: The purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with metastatic or unresectable melanoma with BRAF-mutation positive or wild-type (WT) BRAF, respectively. Phase/Status/Sponsor: Unknown phase; COMPLETED; MedImmune LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma (AJCC Stage IIIB, IIIC, or IV) * Presence of BRAF V600E or…. Goal: This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized. Phase/Status/Sponsor: Unknown phase; COMPLETED; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma is being studied. Conditions: Melanoma and Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: For the dose escalation phase: 1. Histologically confirmed diagnosis of locally advanced or metastatic melanoma (stage IIIB to IV per American Joint Committee on Cancer \[AJCC\]).…. Goal: CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase inhibitor. Patients with locally advanced or metastatic melanoma harboring the BRAF V600 mutation (during dose escalation phase and expansion phase) and patients with metastatic colorectal cancer harboring the BRAF V600 mutation (during the expansion phase) will be enrolled. Phase/Status/Sponsor: Unknown phase; COMPLETED; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients is being studied. Conditions: Malignant Melanoma • Eligibility: Inclusion Criteria: 1. 18 years of age and signed written informed consent. 2. Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and…. Goal: Patients with BRAF V600 mutant advanced melanoma benefit from treatment with a BRAF-inhibitor (e.g. dabrafenib, vemurafenib) and from combination of a BRAF- and MEK-inhibitor (e.g. Phase/Status/Sponsor: Unknown phase; COMPLETED; Universitair Ziekenhuis Brussel.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma +25 • Eligibility: Inclusion Criteria: * Participants must have histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum, with clinical confirmation of unresectable and/or metastatic disease that is…. Goal: This phase I/II trial studies the side effects and how well encorafenib, binimetinib, and nivolumab work in treating patients with microsatellite stable, BRAFV600E gene-mutated colorectal cancer that has spread to other places in the body (metastatic). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) is being studied. Conditions: Malignant Melanoma, Brain Metastases • Eligibility: Inclusion Criteria: * Males and females ≥ 18 years of age * Histologically or cytologically confirmed BRAFV600-mutated melanoma * Documented metastasis of the primary tumor to the CNS…. Goal: This is a Phase 1 study of E6201 plus dabrafenib for the treatment of CNS metastases in BRAF V600-mutated metastatic melanoma. A total of up to N=28-34 subjects with melanoma metastasized to the CNS will be included. Phase/Status/Sponsor: Unknown phase; TERMINATED; Spirita Oncology, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma is being studied. Conditions: Melanoma, Metastatic Melanoma • Eligibility: Inclusion Criteria: 1. Patients must have histological or cytological confirmed melanoma that is metastatic or unresectable stage IIIc and clearly progressive. 2. Patients must have melanoma that is…. Goal: This phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor cobimetinib; or, (2) SOC plus bevacizumab, an anti-VEGF antibody that suppresses new blood vessel formation and can stimulate the immune system. Previous clinical studies in melanoma have shown that bevacizumab may improve clinical benefit (progression free survival) if combined with ipilimumab or abraxane. Phase/Status/Sponsor: Unknown phase; TERMINATED; Melanoma Research Foundation Breakthrough Consortium.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma is being studied. Conditions: Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation • Eligibility: Inclusion Criteria: * Age ≥ 18 years at the time of informed consent * Histologically confirmed diagnosis of melanoma. Any primary or unknown origin is permitted. * Melanoma…. Goal: The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Written informed consent prior to performance of any study procedure. 2. Patient must be ≥18 years of age, at the time of signing the informed…. Goal: This is an open-label, multicenter, randomized study to be conducted in Chinese patients with RAS and BRAF wild-type mCRC. Patients who have already completed 9 cycles of standard first-line induction treatment, without discontinuation for toxicity, of cetuximab or fluorouracil or oxaliplatin,, and achieved disease control (including CR/PR and SD), and are progression free at the end of Cycle 9 will be assigned to 2 maintenance treatment groups by randomization in a 1:1 ratio to receive cetuximab + capecitabine (Arm A) or cetuximab alone (Arm B). Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Provided signed written informed consent. * Males and females \>=18 years of age. * Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or…. Goal: Present clinical study will be conducted in China to evaluate the pharmacokinetics (PK) of single and repeat oral doses of dabrafenib alone and dabrafenib and trametinib in combination, the safety profile and the clinical activity of dabrafenib in combination with trametinib in Chinese melanoma subjects with BRAF V600E/K mutation. Approximately 20 evaluable subjects will be enrolled in the study, out of which, the first 10 subjects will be enrolled into cohort A (Part I and II) and remaining 10 subjects will be enrolled in cohort B. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; GlaxoSmithKline.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: * informed consent to study procedures, male or female， 18-80 years old. * Histologically or cytologically proven diagnosis of unresectable metastatic colorectal cancer * Patients were…. Goal: To assess the efficacy and safety of the combination of CPGJ602 and chemotherapy in subjects with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma is being studied. Conditions: Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma • Eligibility: Inclusion Criteria: * Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma. * The participant has an ECOG performance…. Goal: This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma Phase/Status/Sponsor: Unknown phase; RECRUITING; Iovance Biotherapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC is being studied. Conditions: Colon Cancer • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed colorectal adenocarcinoma, with unresectable metastatic or locally advanced disease documented on diagnostic imaging studies. 2. Previously received 1-2 prior lines of…. Goal: To investigate the combination of nivolumab and ipilimumab with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; UNC Lineberger Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Participants included in the TAU from 26 February 2015 * Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with…. Goal: This is a multicentre, ambispective (both retrospective and prospective), and non-interventional study conducted in France in adult participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with vemurafenib (Zelboraf®). Phase/Status/Sponsor: Unknown phase; COMPLETED; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma is being studied. Conditions: Advanced BRAF-mutant Cancers • Eligibility: Inclusion Criteria: * ≥ 18 years at time of consent * If a sexually active male or a sexually active female of child-bearing potential, agrees to use a…. Goal: The purpose of the phase 1 portion of the study is to determine the maximally tolerated dose (MTD) or recommended dose (RD) and the safety/tolerability of PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. The purpose of the phase 2 portion of the study is to compare progression free survival (PFS), antitumor activity (response rate), disease control rate (DCR), and the safety and tolerability of PX-866 in combination with vemurafenib vs. Phase/Status/Sponsor: Unknown phase; TERMINATED; Cascadian Therapeutics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement is being studied. Conditions: Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary +2 • Eligibility: Inclusion Criteria: * Age ≥16 years at the time of consent * Histologically confirmed diagnosis of advanced/metastatic solid tumor including primary brain tumor * Documented evidence of a…. Goal: First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with and without brain involvement. Phase/Status/Sponsor: Unknown phase; TERMINATED; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Histologically confirmed melanoma of cutaneous origin * Participants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic Stage IIC or Stage III according to AJCC Staging Criteria…. Goal: This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for recurrence. Participants will be enrolled in two separate cohorts: Cohort 1 will include participants with completely resected Stage IIC, IIIA (participants with one or more nodal metastasis greater than \[\>\] 1 millimeter \[mm\] in diameter), or IIIB cutaneous melanoma, as defined by the American Joint Committee on Cancer (AJCC) Classification, Version 7; Cohort 2 will include participants with Stage IIIC cutaneous melanoma, as defined by this classification scheme. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers is being studied. Conditions: Multiple Myeloma, Neoplasms • Eligibility: Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Must have recovered from all side effects of their most recent systemic or local treatment…. Goal: This open-label, multi-center study will assess the efficacy and safety of vemurafenib in participants with BRAF V600 mutation-positive cancers (solid tumors and multiple myeloma, except melanoma and papillary thyroid cancer) and for whom vemurafenib is deemed the best treatment option in the opinion of the investigator. Participants will receive twice daily oral doses of 960 mg vemurafenib until disease progression, unacceptable toxicity, or withdrawal of consent. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations is being studied. Conditions: Melanoma, BRAF V600 Mutation, Unresectable Melanoma +1 • Eligibility: Inclusion Criteria: 1. Healthy participant. 2. Female participants must be postmenopausal or sterilized. 3. Body mass index (BMI) of ≥ 18.5 to \< 30 kg/m2, with body weight…. Goal: The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration. For the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation, the recommended dosing regimen is 45 mg twice daily (bis in die, BID). Phase/Status/Sponsor: Unknown phase; UNKNOWN; Pierre Fabre Medicament.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion criteria 1. Willing and able to give written informed consent. 2. ECOG performance status ≤ 1 3. Histologic diagnosis of unresectable stage IIIC or stage IV melanoma…. Goal: The purpose of this study is to evaluate the safety of combination therapy with vemurafenib and trientine in patients with BRAF mutated metastatic melanoma. Vemurafenib is a drug that is currently approved by the United States Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) to treat adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery. Phase/Status/Sponsor: Unknown phase; WITHDRAWN; Duke University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids is being studied. Conditions: Glioblastoma, Brain Tumor, Cannabis +1 • Eligibility: Inclusion Criteria: * Histological diagnosis of MGMT promoter methylated, IDH wild type (WT) GBM with consistent local molecular pathology (repeat biopsy at recurrence is NOT required). * First…. Goal: ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to compare the cannabinoid Nabiximols with placebo in patients with recurrent MGMT methylated glioblastoma (GBM) treated with temozolomide (TMZ). Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors is being studied. Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +14 • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is considered surgically incurable with either: * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis…. Goal: This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anusha Kalbasi.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests BOLD-100 given with the chemotherapy FOLFOX in adults with advanced gastrointestinal cancers (such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma) to assess safety and tolerability, using a dose-escalation phase followed by expansion. - In the colorectal cancer arm (Arm VII), eligible patients who are oxaliplatin-naïve and have had only one prior metastatic therapy will be randomized to three groups: BOLD-100 at 500 mg/m2 with FOLFOX, BOLD-100 at 625 mg/m2 with FOLFOX, or FOLFOX alone, with quality-of-life assessments. - The trial aims to learn whether adding BOLD-100 provides anti-tumor activity and how it affects patients’ quality of life, while establishing safe dose levels. - Key exclusions include neuropathy greater than grade 2, CNS metastases, active HIV on ART, DPD deficiency, prior exposure to BOLD-100 (for Arm VII), MSI-H tumors, and recent major treatments or other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) is being studied. Conditions: Colorectal Neoplasms • Eligibility: The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: Inclusion Criteria include, but are not limited to: * Has a histologically…. Goal: In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Cancer Metastatic • Eligibility: Inclusion Criteria: * Signed written Informed Consent. * Male and female subjects aged greater than or equal to18 years. * Eastern Cooperative Oncology Group (ECOG) Performance Score 0…. Goal: This study aims to determine the safety and best response of treatment with CNA3103 (Leucine-rich repeat-containing G protein-coupled receptor 5 \[LGR5\]-targeted, Autologous Chimeric Antigen Receptor (CAR) -T Cells), for participants with Metastatic Colorectal Cancer. Participants may undergo a pre-screening biopsy procedure to determine expression of LGR5. Phase/Status/Sponsor: Unknown phase; RECRUITING; Carina Biotech Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer is being studied. Conditions: Metastatic Colon Cancer, Stage III Colon Cancer • Eligibility: Inclusion Criteria: * Participants must have histologically confirmed resected Stage III adenocarcinoma of the colon. Any T \[Tx, T1, T2, T3, or T4-\], N1-2M0. * Participants must have…. Goal: This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies is being studied. Conditions: Cushing's Disease, Acromegaly, Neuroendocrine Tumors +6 • Eligibility: Inclusion Criteria: 1. Patient is currently participating in a Novartis-sponsored study receiving pasireotide (LAR and/or s.c.) on monotherapy or combination therapy (for Cushing's Disease or Acromegaly), and has…. Goal: The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator. Phase/Status/Sponsor: Unknown phase; COMPLETED; RECORDATI GROUP.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of IK-595 in RAS- or RAF-altered Advanced Tumors is being studied. Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: 1. Patients ≥ 18 years of age. 2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 3. Adequate organ function as…. Goal: This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit. Phase/Status/Sponsor: Unknown phase; TERMINATED; Ikena Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma is being studied. Conditions: Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma +1 • Eligibility: Inclusion Criteria: Cohort 1: Must have a confirmed diagnosis of metastatic Uveal Melanoma. * Patients will be eligible regardless of the number of prior systemic therapies received. *…. Goal: This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma is being studied. Conditions: Advanced (Unresectable or Metastatic) Melanoma • Eligibility: Inclusion Criteria: 1. Age ≥18 years at the time of signing the informed consent (or adulthood where the legalage of majority in the country is established \>18 years).…. Goal: This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma Phase/Status/Sponsor: Unknown phase; RECRUITING; mAbxience Research S.L..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether the molecular results from a fine needle biopsy (FNB) using Thyroid GuidePx® are the same as results from the larger surgical tissue in people with papillary thyroid cancer. It is for adults with a preoperative diagnosis of papillary thyroid cancer (Bethesda V/VI) or indeterminate nodules (Bethesda III/IV) who are candidates for thyroidectomy. During surgery, an FNB of the dominant tumor will be taken and both the FNB and surgical samples will undergo RNASeq to see if the FNB can reliably classify the cancer. The goal is to find out if the smaller biopsy is sufficiently representative to guide treatment decisions before surgery. Exclusions include history of neck radiation, inability or unwillingness to have a fine needle biopsy or thyroidectomy, final pathology not showing papillary thyroid cancer, or situations with no clear dominant nodule or multiple nodules precluding sampling.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma is being studied. Conditions: Melanoma, Unresectable Melanoma • Eligibility: Inclusion Criteria: * Patients must have signed and dated an Institutional Review Board/Independent Ethics Committee -approved written informed consent form in accordance with regulatory and institutional guidelines. This…. Goal: This study will evaluate how safe the study drug is, how well patients tolerate it, how it works in the body, and the disease's response to the drug. The study drug being tested is sarilumab, when given with the combination of ipilimumab, nivolumab, and relatlimab in patients like yourself, with stage III or stage IV melanoma that cannot be removed by surgery. Phase/Status/Sponsor: Unknown phase; RECRUITING; NYU Langone Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma is being studied. Conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma +2 • Eligibility: Inclusion Criteria: * COHORT A and COHORT B: For the dose escalation phase, patients must be ≥ 12 months and \< 18 years of age at the time…. Goal: This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma. AZD1390 is in a class of medications called kinase inhibitors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Children's Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * 1\. Voluntarily participate in the study, communicate well with investigators, understand and voluntarily complete the study process according to this protocol, and sign the informed…. Goal: Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%) Phase/Status/Sponsor: Unknown phase; RECRUITING; HC Biopharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer is being studied. Conditions: Previously Treated Non-Small Cell Lung Cancer • Eligibility: 5.1 Registration Step 0: 1. Patients who need the fresh biopsy must also submit whole blood for ctDNA testing (see Section 15.3). These patients must be registered to…. Goal: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Personalised Immunotherapy Platform is being studied. Conditions: Melanoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma +2 • Eligibility: MELANOMA: Inclusion Criteria: 1. Written informed consent to participation for the use of tumour tissue, blood and stool and collection of standard clinical data. 2. Histologically confirmed resected…. Goal: This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours. The study will evaluate the documentation, processes, accuracy and utility of the predictive biomarker model in clinical practice. Phase/Status/Sponsor: Unknown phase; RECRUITING; Melanoma Institute Australia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma is being studied. Conditions: Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma +1 • Eligibility: Inclusion Criteria: * Confirmed unresectable and/or metastatic cutaneous melanoma. * 2 copies of the fully functional form of GPER protein-coding sequence. * Eligible for and willing to receive…. Goal: The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Phase/Status/Sponsor: Unknown phase; RECRUITING; Linnaeus Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer +1 • Eligibility: Inclusion Criteria Patients who meet ALL the following inclusion criteria will be eligible to participate in the study: 1. ≥18 years of age. 2. Histologically confirmed, locally advanced,…. Goal: The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work. Phase/Status/Sponsor: Unknown phase; RECRUITING; JiaRay Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study is testing a combination of pembrolizumab and lenvatinib for people with anaplastic thyroid cancer. It is recruiting adults in Russia whose cancer cannot be fully removed by surgery and who have a reasonably good performance status. The trial aims to find out whether this drug combination can effectively treat the cancer and how safe it is, with responses measured using iRECIST criteria. Key exclusions include BRAF V600 mutations without prior targeted therapy, significant bleeding risk or invasion into large vessels, pregnancy, and poor functional status.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer is being studied. Conditions: Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma +16 • Eligibility: Inclusion Criteria: * Age 18 or over * Histologically or cytologically documented advanced or metastatic cancer that has relapsed from or is refractory to standard treatment in two…. Goal: Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases is being studied. Conditions: Brain Metastases, Tumor • Eligibility: Inclusion Criteria: Patients are eligible to be included in the study only if all the following criteria apply: 1. Male/female patients who are at least 18 years of…. Goal: This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and solid tumor types other than TNBC and NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study looks at real-world outcomes for adults with anaplastic thyroid cancer (ATC) or poorly differentiated thyroid cancer (PDTC) and compares overall survival for patients treated at MD Anderson Cancer Center versus those treated elsewhere using MD Anderson regimens based on BRAF status and cancer stage. It aims to learn about barriers to accessing treatments in the real world and how patients tolerate and respond to commercially available medications outside of a clinical trial. The study will collect real-world data on patients who can’t participate in traditional trials but are treated with MD Anderson regimens, grouped by stage and BRAF status. Secondary goals include assessing how chemotherapy, immunotherapy, and radiation affect quality of life, and how factors like health insurance and other sociodemographic characteristics influence outcomes. Eligibility requires adults 18+ with ATC or PDTC; those without ATC/PDTC confirmed on tumor tissue are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Must be ≥ 18 years of age when signing informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 without deterioration in…. Goal: This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; L & L Bio Co., Ltd., Ningbo, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Advanced Cancer, Renal Cancer +15 • Eligibility: Major Inclusion Criteria: 1. Men and women 18 years of age or older. 2. 9 cohorts will be enrolled: * Cohort A1 / Exon 14 NSCLC MET inhibitor…. Goal: To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I) Phase/Status/Sponsor: Unknown phase; RECRUITING; Apollomics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Males or females aged 18 - 75 years (inclusive). * Histologically confirmed unresectable, recurrent or metastatic solid tumors. * At least one target lesion per…. Goal: HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hansoh BioMedical R&D Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients is being studied. Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer • Eligibility: Inclusion: 1. Age ≥18 years on day of signing informed consent. 2. Specific by tumor cohorts: a. For the HSNCC cohort, histologically confirmed diagnosis of advanced and/or metastatic…. Goal: This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Vyriad, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion criteria: * Participant must have histologically or cytologically confirmed metastatic NSCLC characterized by a KRAS G12C mutation at the time of enrollment. For Phase 1: Participant must…. Goal: The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation \[change\] in the kirsten rat sarcoma viral oncogene homolog \[KRAS\] gene in tumor cells in which glycine \[G\] at position 12 is replaced with cystine \[C\]). Phase/Status/Sponsor: Unknown phase; RECRUITING; Janssen Research & Development, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer is being studied. Conditions: Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer +1 • Eligibility: Inclusion Criteria: 1. Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma or Stage III or IV NSCLC. 2. Participants who…. Goal: This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Iovance Biotherapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers is being studied. Conditions: Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor • Eligibility: Inclusion Criteria: Molecular Pre-screening Inclusion criteria 1. cMET amplification in tumor sample; OR 2. cMET overexpression in tumor sample; OR 3. EGFR overexpression in tumor sample; OR 4.…. Goal: This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai EpimAb Biotherapeutics Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases is being studied. Conditions: Colorectal Cancer, Liver Metastases • Eligibility: Inclusion Criteria: * Must reside in Canada * ECOG ( Eastern Cooperative Oncology Group) score : 0-1 at all times prior to LDLT (excursions to ECOG 2 allowed…. Goal: Patients with unresectable liver metastases (LM) from colorectal cancer (CRC)have a poor prognosis. In patients with resectable disease, surgery offers a distinct survival benefit. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Health Network, Toronto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a single-arm, dose-escalation phase I trial testing a CAR-T cell therapy called C-13-60 that targets CEA, to evaluate safety, tolerability, and how the drug behaves in the body, with early signs of activity. - It is for adults 18 and older with advanced CEA-positive solid cancers (such as colorectal, esophageal, gastric, pancreatic, non-small cell lung, breast, or cholangiocarcinoma) whose disease has progressed after standard treatments and who cannot have surgery or local therapy. - The study also aims to observe preliminary anti-tumor efficacy to help determine a dose regimen for future phase II trials. - Key exclusions include prior CAR-T or other gene-modified cell therapy, active infections or uncontrolled autoimmune disease, pregnancy or planning pregnancy, and certain heart or brain conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment is being studied. Conditions: Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Age 18 years or older 2. Willingness to provide written informed consent. 3. Life expectancy \>12 weeks. 4. Eastern Cooperative Oncology Group (ECOG) performance status…. Goal: This is an interventional, non-pharmacologic, randomized controlled study evaluating the impact on quality of life of a personalized exercise program in oncogene addicted lung cancer patients undergoing active treatment. Patients will be randomized 1:1 in two arms: arm A (interventional) and arm B (control). Phase/Status/Sponsor: Unknown phase; RECRUITING; AUSL Romagna Rimini.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (ICF); voluntarily participate…. Goal: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Henlius Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy is being studied. Conditions: Metastatic Melanoma • Eligibility: Inclusion Criteria: * Age greater than or equal to 18 years, * Patient with advanced melanoma proved histologically, not BRAF mutated, BRAFV600 mutated and wild mutated, cutaneous or…. Goal: The objective of this study is to assess whether FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET-CT could be an early predictive method of therapeutic response to anti-PD-1 immunotherapy in metastatic melanoma after 2 cycles of ANTI-PD1. 20 patients will be enrolled and undergo three PET/CT scans: a baseline PET-CT, an early research PET-CT after 2 cycles of anti-PD1 (PET1) and a PET-CT at 3 months of initiation of treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Hospitalier Universitaire de Nice.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Patients with stage III non-small cell lung cancer were confirmed by imaging and histological biopsy 2. Age≥ 18 3. ECOG PS:0-1 4. Tumor molecular testing…. Goal: The goal of this prospective, observational study is to explore the value of dynamic monitoring of minimal residual lesions in driver mutated stage III NSCLC for disease recurrence and prognosis assessment. The main question it aims to answer is: 1\) Whether MRD(Minimal residual disease) status can predict recurrence events in stage III driven-mutant NSCLC in advance Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Chest Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TSN222 in Subjects With Advanced Solid Tumors or Lymphomas is being studied. Conditions: Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma • Eligibility: Inclusion Criteria: Subjects must meet all the following inclusion criteria to be eligible for participation in this study: 1. The subject fully understands the requirements of the study…. Goal: The study is a first-in-human \[FIH\], open-label phase 1/2 study of TSN222 in subjects with advanced solid tumors or lymphomas. This study is comprised of a Phase 1 dose escalation and Phase 2 dose expansion component. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tyligand Bioscience (Shanghai) Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Efficacy and Safety of IBI363 in Solid Tumors is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Sign written informed consent before implementing any trial-related procedures * Age ≥18 years old and ≤75 years old; * No limit on the gender; *…. Goal: The study is a prospective multi-cohort clinical study. The study is divided into two phases, Phase Ia and Phase Ib. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hunan Province Tumor Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a drug called MGC028 in adults whose ADAM9-expressing solid tumors are relapsed or refractory, unresectable, locally advanced, or metastatic. - It uses dose escalation to find a safe dose and to describe safety and side effects, including any dose-limiting toxicities and the highest dose that can be given safely. - The trial also aims to learn whether MGC028 can shrink tumors, keep cancer from growing, or control disease in these advanced cancers. - Cancers eligible for participation include NSCLC adenocarcinoma, cholangiocarcinoma, colorectal cancer, and pancreatic cancer with specific prior-treatment criteria; key exclusions include active brain metastases, prior ADAM9-targeted therapy, recent major cancer treatment, organ transplant, infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care is being studied. Conditions: NSCLC, Melanoma • Eligibility: Inclusion Criteria To participate in this study a participant must meet the eligibility of one of the following cohorts: Cohort 1: Cancers beginning initial treatment * One of…. Goal: Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma, and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by availability of tumor biopsy tissue for testing. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer is being studied. Conditions: Unresectable/Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Metastatic or locally advanced, unresectable colorectal cancer confirmed by histology or cytology 2. The occurrence of metastases after radical resection of colorectal cancer does not…. Goal: FOLFOXIRI-based regimen is more used as a first-line therapeutic approach for patients diagnosed with unresectable or metastatic colorectal cancer for its superior efficacy. However, there are no standard recommendations for second-line therapy after progression on FOLFOXIRI with or without targeted therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases is being studied. Conditions: NSCLC Stage IV Without EGFR/ALK Mutation • Eligibility: Inclusion Criteria: * Patient must meet all of the following inclusion criteria to be enrolled in this study: 1. Non-small cell lung cancer diagnosed initially through pathological histology.…. Goal: It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases. At the same time, by using multimodal omics data, machine learning will be employed to construct a prediction model for the abscopal effect, and explore the immunoregulation of organ-specific radiotherapy and biomarkers of the abscopal effect. Phase/Status/Sponsor: Unknown phase; RECRUITING; Xinqiao Hospital of Chongqing.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years at the time of informed consent 2. Patient must be able to provide informed consent. 3. Patient must have a histologically…. Goal: The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: To participate in the study, participants must meet all the following inclusion criteria: Cohort A only: 1. Prior treatment with anti-PD-(L)1 therapy (for example, pembrolizumab or…. Goal: This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Agenus Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors is being studied. Conditions: HNSCC, Melanoma, Gynecologic Cancer +3 • Eligibility: Inclusion Criteria * Participants must have signed and dated a current IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. Patients must have the…. Goal: The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies. The TIL selection process is based on evidence showing that CD8+ TIL which co-express both CD39 and CD103 harbor the bulk of tumor-reactivity and that the remaining CD8 TIL is mainly composed of non-tumor reactive bystander cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AgonOx, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ACT-TIL and ANV419 for Advanced Melanoma. is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: Patients who meet all the following criteria will be eligible to participate in the study: * Must provide written informed consent for the study. * Must…. Goal: In this study we aim to investigate safety and tolerability of tumor-infiltrating lymphocytes (TIL) adoptive cell therapy (ACT) incorporation in-vivo TIL expansion with ANV419 in patients with advanced melanoma Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University Hospital, Basel, Switzerland.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ultrasound-guided Thermal Ablation for Bethesda III/IV Thyroid Nodules is being studied. Conditions: Thyroid Nodule • Eligibility: Inclusion Criteria: 1. confirmation of Bethesda III or IV on fine- needle aspiration and negative on Braf V600E test 2. no clinical or imaging evidences of extrathyroidal extension,…. Goal: To evaluate the long-term outcomes of ultrasound-guided thermal ablation for Bethesda III/IV thyroid nodules Phase/Status/Sponsor: Unknown phase; RECRUITING; Chinese PLA General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Patients with histologically proven metastatic colorectal cancer in progression after a first line of chemotherapy +/- targeted therapy 2. Patients must have been treated for…. Goal: This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Hospitalier Universitaire de Besancon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor +11 • Eligibility: Inclusion Criteria: Patients eligible for inclusion in this study have to meet all of the following criteria: * Patients, 18 years of age or older * Competent and…. Goal: The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA. Among these, the Next generation sequencing (NGS) is a technique that consists in sequencing several genomes in a short time span, collecting information about a wider range of genomic alterations, using small quantities of genetic material. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centro di Riferimento Oncologico - Aviano.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Predictive Value of PREMM5, MMRpredict, and Universal Tumor Screening for Lynch Syndrome in Vietnam is being studied. Conditions: Lynch Syndrome, Colorectal Cancer (CRC) • Eligibility: Inclusion Criteria: * Aged 18 to 70 years * Provide informed consent to participate in the study * Undergo colonoscopy with endoscopic findings suspicious for CRC * Have…. Goal: This study evaluates the predictive value of PREMM5, MMRpredict models, and Universal Tumor Screening in detecting Lynch Syndrome in colorectal cancer (CRC) patients in Vietnam. Vietnamese CRC patients (18-70 years) undergoing colonoscopy will be enrolled. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University of Medicine and Pharmacy at Ho Chi Minh City.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease is being studied. Conditions: Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8 +7 • Eligibility: Inclusion Criteria: * Patients must have radiographic and/or CSF cytological evidence of LMD. For patient with melanoma: Must have a confirmed diagnosis of primary central nervous system (CNS)…. Goal: This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. is being studied. Conditions: CRC • Eligibility: Inclusion Criteria: * Males or females, aged ≥ 18 years. * Participants with pathologically confirmed advanced Colorectal Cancer. * Participants have at least 1 target lesion other than…. Goal: This is a multicenter, open-label Phase Ib/II clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of the HS-20110 combination therapies in Patients with Advanced Colorectal Cancer. "Rolling 6" design would be used to conduct dose escalation part of this study. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Hansoh BioMedical R&D Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) is being studied. Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma +3 • Eligibility: Inclusion Criteria: * Participants must be assigned to S1900E. Assignment to S1900E is determined by the LUNGMAP protocol genomic profiling using the FoundationOne assay. Biomarker eligibility for S1900E…. Goal: This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an electrocardiogram (ECG)…. Goal: This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a genetic change called PTEN mutation or deletion. GSK2636771 may block a protein called PI3K-beta, which may be needed for growth of cancer cells that express PTEN mutations. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers is being studied. Conditions: Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer +3 • Eligibility: Diagnosis and Main Criteria for Inclusion/Exclusion: Inclusion Criteria Main Study - patients with MSS mCRC These criteria are applicable for both Dose Escalation and Expansion part of the…. Goal: This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Rottapharm Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Selumetinib and Olaparib in Solid Tumors is being studied. Conditions: Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs +2 • Eligibility: Inclusion Criteria: 1. Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations. 2. Age \>/= 18 years at time of study…. Goal: This study has 2 phases: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose combination of selumetinib and olaparib that can be given to patients who have solid tumors that are advanced or recurrent (has returned after treatment). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma is being studied. Conditions: Malignant Melanoma • Eligibility: Inclusion Criteria: 1. Have fully understood the study and voluntarily signed the informed consent; 2. Age 18-75 years old (including 18 and 75 years old), gender is not…. Goal: This single-arm, multicenter clinical study enrolled patients with advanced malignant melanoma who had failed previous first-line therapy (cutaneous melanoma patients were excluded), and patients with BRAF V600 mutations required targeted therapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer is being studied. Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 • Eligibility: Inclusion Criteria: * Participants with Stage IV or recurrent/metastatic histologically confirmed non-small cell lung cancer (NSCLC). * NSCLC must harbor at least one of the following EGFR activating…. Goal: This phase I trial tests the safety, side effects, and best dose of osimertinib, cetuximab, and tucatinib in treating patients with EFGR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent). Osimertinib and tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Jonathan Riess.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests molecular analyses of blood, tumor tissue, normal tissue, and other body fluids to learn about cancer development, growth, and spread. - It is for adults with thoracic cancers: non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, mesothelioma, or cancer of unknown primary presenting in the chest. - The goal is to identify markers that help diagnose cancer, predict outcomes, and predict response to targeted therapies, and to find targets for new treatments. - The project aims to create a registry of patients and tumors to better understand molecular changes in thoracic cancers and aid early detection. - Enrollment is by invitation, and participants must be able to give informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an AKT mutation…. Goal: This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) is being studied. Conditions: Malignant Solid Neoplasm • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol * Patients must fulfill all…. Goal: The phase II MATCH treatment trial tests how well copanlisib works to treat patients with cancer with PTEN loss. Copanlisib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma is being studied. Conditions: Tumor, Metastatic Melanoma, Melanoma • Eligibility: Inclusion Criteria: 1. Male or female patients age ≥ 18 at the time of signing ICF 2. Patient has a pathologically confirmed diagnosis of metastatic melanoma that is…. Goal: The goal of this clinical research study is to find the recommended dose of OBX-115 in combination with acetazolamide that can be given to patients with metastatic melanoma previously treated with immune checkpoint inhibitors. The safety and tolerability of the study drug combination will also be studied. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC is being studied. Conditions: Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer • Eligibility: Inclusion Criteria: * Voluntarily signs the informed consent form. * Aged between 18 and 80 years (inclusive) at the time of consent; no gender restriction. * Histologically confirmed…. Goal: This is a single-arm, multi-center, exploratory study evaluating the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with bevacizumab for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic colorectal cancer. Eligible participants who meet the inclusion and exclusion criteria will provide written informed consent and receive QL1706 at 5.0 mg/kg and bevacizumab at 7.5 mg/kg on Day 1 of every 3-week cycle (Q3W), until disease progression or completion of 2 years of treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Qianfoshan Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a patient-specific neoantigen vaccine (GRT-C901 followed by GRT-R902) given with immune checkpoint blockers and standard fluoropyrimidine/bevacizumab chemotherapy for metastatic colorectal cancer. - In Phase 2, it compares this vaccine-plus-immunotherapy approach to fluoropyrimidine/bevacizumab alone to see if it produces a molecular response measured by circulating tumor DNA. - In Phase 3, the trial aims to show clinical benefit by improving progression-free survival. - It is for adults with metastatic colorectal cancer who are planned for or recently treated with first-line regimens and have measurable disease and adequate organ function. - Key exclusions include dMMR/MSI-H tumors, BRAFV600E mutations, immune suppression or autoimmune disease, active CNS metastases, active infection or HIV/hepatitis, recent other cancer, and pregnancy; the study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients is being studied. Conditions: Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +2 • Eligibility: Inclusion Criteria: * Patient must be 18 to 75 years of age * Must have a confirmed diagnosis of Stage IIIB-D locally advanced or Stage IV melanoma (American…. Goal: This phase I/II trial tests the safety and side effects of LN-144 (Lifileucel) and pembrolizumab in treating patients with stage IIIB-D or stage IV melanoma that has spread to nearby tissue or lymph nodes. Biological therapies, such as LN-144 (Lifileucel), use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Richard Wu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) is being studied. Conditions: Melanoma, Ocular Melanoma, Uveal Melanoma • Eligibility: Main Inclusion Criteria: 1. a. For individuals with primary cutaneous, mucosal, or unknown melanoma, an individual must have stage IB ulcerated, II, III, or IV melanoma at original…. Goal: This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). Phase/Status/Sponsor: Unknown phase; COMPLETED; Craig L Slingluff, Jr.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer is being studied. Conditions: Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer +1 • Eligibility: Inclusion Criteria: * Have advanced or metastatic cancer (solid tumors) and be an appropriate candidate for experimental therapy. * Part B (No Longer Enrolling Participants): Have advanced or…. Goal: The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Eli Lilly and Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) +1 • Eligibility: Inclusion Criteria: * Must be ≥18 years of age * Must have histologically or cytologically confirmed diagnosis as follows: 1. Monotherapy Phase 1: A locally advanced unresectable or…. Goal: This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Immuneering Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen is being studied. Conditions: Metastatic Colorectal Adenocarcinoma • Eligibility: Inclusion Criteria: 1. Histologically proven diagnosis of colorectal adenocarcinoma 2. Diagnosis of metastatic disease 3. RAS and BRAF wild-type status of FFPE analysis of primary colorectal cancer and/or…. Goal: This clinical program aims to evaluate the activity and efficacy of cetuximab continuation of treatment for three lines of therapy with rotation of chemotherapy (FOLFIRI, FOLFOX, irinotecan) in mCRC patients, whose tumors remain RAS/BRAF WT. The study will also evaluate the activity and efficacy of cetuximab re-introduction in combination with irinotecan as third line therapy in the concept of re-challenge for those patients that will be treated in second line with chemotherapy plus anti-angiogenic drugs (FOLFOX plus bevacizumab), having a RAS or BRAF mutant disease at the time of progression after FOLFIRI plus cetuximab first line treatment. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Campania Luigi Vanvitelli.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Provide written informed consent to participate in the study voluntarily. 2. Male or female aged 18-75. 3. Metastatic colorectal adenocarcinoma confirmed by histology or cytology.…. Goal: The goal of this prospective clinical trial is to evaluate efficacy and safety of irinotecan liposomes for first-line treatment of advanced colorectal cancer. The primary endpoint is Objective response rate (ORR) per RECIST 1.1. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9 is being studied. Conditions: Acute Myeloid Leukemia, Melanoma, Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Diagnosis of acute myeloid leukemia (AML) and fit for allogeneic hematopoietic stem cell transplantation (alloHSCT), as assessed in the standard operating procedures. * Diagnosis of…. Goal: This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Turku University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors is being studied. Conditions: Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma +2 • Eligibility: Inclusion Criteria: * Cytologically or histologically confirmed solid tumor that is inoperable locally advanced, metastatic, or recurrent. * Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor…. Goal: This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Exelixis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TIL and Anti-PD1 in Metastatic Melanoma is being studied. Conditions: Toxicity, Drug, Adverse Drug Event, Effects of Immunotherapy • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Histologically or cytologically proven metastatic skin melanoma 3. Melanoma must be at one of the following AJCC 2009 stages: *…. Goal: The ACTME study is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma. The trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Leiden University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET) is being studied. Conditions: Advanced / Metastic Solid Tumors, Glioblastoma, Chronic Leukemia Lymphocytic • Eligibility: Inclusion Criteria: I1. Adult male or female patient with confirmed diagnosis of advanced/metastatic cancer to be treated with standard anti-cancer treatment according to : * For metastatic Small…. Goal: The proposal is to conduct a prospective, multi-cohort study aiming to decipher molecular profiles/biological characteristics of advanced cancer patients during the course of their disease with longitudinal and sequential analyses of tumor and liquid biopsies. This approach will allow i) to develop a model in order to predict tumor response / resistance in real life conditions and to better understand adaptive mechanisms and ii) to potentially propose therapeutic options to enrolled patients following the review of the biological/molecular data generated during this study and during a Molecular Tumor Board in case of disease progression. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Centre Leon Berard.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) is being studied. Conditions: Solid Tumors, GI Cancer • Eligibility: Inclusion Criteria The following criteria must be met by ALL subjects 1. Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Phase 1) or…. Goal: This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both phases are to evaluate safety, pharmacokinetics, and clinical activity. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Curegenix Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * Patients with newly diagnosed stage IV colon or rectal cancer who are RAS/BRAF wild-type by routine tumor profiling and who are beginning standard-of-care treatment with…. Goal: The study aims to explore the clinical utility of circulating tumour DNA (ctDNA) in assessing for alterations of anti-epidermal growth factor receptor (EGFR) primary resistance in RAS and BRAF wild-type metastatic colorectal cancer (CRC) patients treated with anti-EGFR monoclonal antibodies (cetuximab / panitumumab) in combination with fluorouracil (FU)-doublet chemotherapy. Phase/Status/Sponsor: Unknown phase; UNKNOWN; National University Hospital, Singapore.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether using a Medtronic pump with a Codman catheter to deliver chemotherapy directly into the liver is a safe alternative to the C3000 Codman pump for people with liver metastases from colorectal cancer or cholangiocarcinoma. It includes adults with liver metastases from colorectal cancer (unresectable or resectable) and adults with unresectable cholangiocarcinoma. Participants will receive systemic chemotherapy (various regimens) starting about four weeks after the pump is placed. Key exclusions include active infection or hepatitis, pregnancy, prior liver-directed radiation, brain metastases or seizures, certain genetic cancer types (e.g., BRAF mutation or mismatch repair deficiency), and other serious medical problems.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation is being studied. Conditions: Breast Cancer Female • Eligibility: Inclusion Criteria: In order to be eligible for participation in this trial, the subject must: 1. Be willing and able to provide written informed consent/assent for the trial.…. Goal: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) designed to directly block the interaction between PD-1 and its ligands and enable the T cell to remain active and co-ordinate an attack on tumor cells. We hypothesise that the Clinical Benefit Rate (CBR) and progression free survival (PFS) of metastatic breast cancer patients who have ESR1 mutation will improve following administration of a combination of pembrolizumab and tamoxifen. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Mediclinic Middle East.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: 1. Histologically confirmed mucosal melanoma with metastases and has no received any systemic treatment. 2. ECOG performance status 0, 1 3. Estimated life expectancy of 12…. Goal: Mucosal melanoma is rare and associated with extremely poor prognosis.No effective treatment for advanced mucosal melanoma patients.Investigators conducted a randomized phase II study in patients with previously untreated metastatic mucosal melanoma to characterize the efficacy and safety of bevacizumab when combined with carboplatin plus paclitaxel. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Peking University Cancer Hospital & Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients is being studied. Conditions: Fruquintinib, Irinotecan, Capecitabine +1 • Eligibility: Inclusion Criteria: 1. Subjects voluntarily enrolled in the study and signed an informed consent form, were compliant and cooperated with follow-up visits; 2. Patients with metastatic colorectal adenocarcinoma…. Goal: This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; China Medical University, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents is being studied. Conditions: Cancer, Tumor, Solid, Malignant Neoplasm +7 • Eligibility: Inclusion Criteria: 1. Informed consent signed by the subject prior to conducting study-specific procedures. 2. Male or female subjects ≥ 18 and ≤ 100 years of age. 3.…. Goal: This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; UNKNOWN; OncoResponse, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) is being studied. Conditions: Melanoma • Eligibility: Inclusion criteria: * Unresectable (Stage III) or metastatic melanoma * Failed or progressed on standard of care systemic therapy including ipilimumab (with the exception of a participant with…. Goal: This is an expanded access program (EAP) for participants who have progressed after prior systemic therapy including ipilimumab, and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor or mitogen-activated protein kinase (MEK) enzyme inhibitor when indicated. Participants cannot be eligible for or have participated in any pembrolizumab (MK-3475) clinical trial with the exception of a participant enrolled in the pembrolizumab protocol MK-3475-006 who received treatment on the ipilimumab treatment arm and progressed; such participants will be eligible to participate in the EAP, regardless of prior treatment with a BRAF/MEK inhibitor, as long as all other eligibility criteria for MK-3475-030 are met. Phase/Status/Sponsor: Unknown phase; NO_LONGER_AVAILABLE; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: 1. Be willing and able to give written informed consent for the study. 2. Be ≥ 18 years of age on day of informed consent. 3.…. Goal: This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma that have progressed on anti-PD-1-containing treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Highlight Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation is being studied. Conditions: Liver Metastases, Colorectal Cancer Metastatic, Liver Neoplasm +1 • Eligibility: Inclusion Criteria: * Histologically confirmed non-mucinous colon adenocarcinoma. * Primary tumor as pT1-3, pN0 or pN1 (metastases in \< 4 regional lymph nodes), confirmed R0 resection. * RAS…. Goal: The COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial, aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation (LT) in liver-only CRC metastases, compared with a matched cohort of patients bearing the same tumor characteristics, collected during the same time period and included in a phase III Italian RCT on triplet chemotherapy+antiEGFR Phase/Status/Sponsor: Unknown phase; UNKNOWN; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors is being studied. Conditions: Neoplasms, Melanoma • Eligibility: Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 2. For both the dose escalation and expansion cohort phases of the study, eligible participants must…. Goal: This study has 2 phases. The main aims of Phase 1b are: * to check for side effects from modakafusp alfa in adults with locally advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Teva Branded Pharmaceutical Products R&D LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy is being studied. Conditions: Metastatic Colorectal Cancer, Pancreas Adenocarcinoma, Cholangiocarcinoma • Eligibility: Inclusion Criteria: Newly referred patients with advanced pancreatic cancer (\~20/year), Cholangiocarcinoma (\~20/year), metastatic colorectal cancer (mCRC) (\~50/year) and anti-EGFR-treated mCRC patients (\~10/year) to Oslo University Hospital are eligible…. Goal: Circulating tumor DNA assays are becoming relevant for routine diagnostics, but many related aspects are yet unresolved. With this project, the investigators aim to develop pragmatic molecular diagnostic pathways of liquid biopsies relevant in advanced gastrointestinal malignancies with focus on clinical utility and sensible use of resources. Phase/Status/Sponsor: Unknown phase; TERMINATED; Oslo University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Voluntary agreement to provide written informed consent. * Predicted survival ≥ 12 weeks. * According to UICC/AJCC 8th Edition, histologically and/or cytologically-confirmed, cannot be surgically…. Goal: This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection combined with pyrotinib in subjects with local advanced or metastatic non-small cell lung cancer with HER2 mutation. Phase/Status/Sponsor: Unknown phase; UNKNOWN; RemeGen Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: Only the patients meeting all the following criteria can be eligible to participate in the trial: * Fully informed consent and signed ICF; * Age of…. Goal: This is a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with chemotherapy in Advanced Non-small Cell Lung Cancer (NSCLC) Participants with TKI-resistant EGFR-mutated Tumors; and evaluate the population with the best predictive biomarkers, i.e., positive diagnosis population. About 440 subjects with advanced non-small cell lung cancer with activated EGFR mutation will be 1:1 randomized into two groups, JS001 combined with the standard 1st-line chemotherapy will be given in the study group whereas placebo combined with standard 1st-line chemotherapy will be given in the control group. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Shanghai Junshi Bioscience Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma is being studied. Conditions: Melanoma Stage Iv, Melanoma Stage Iii, Melanoma • Eligibility: Inclusion Criteria: 1. Histologically confirmed unresectable or metastatic melanoma as per AJCC 7 staging system. 2. Age ≥ 18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status…. Goal: The purpose of this project is to test the addition of a new treatment called denosumab to standard immunotherapies for patients with metastatic melanoma. Denosumab has been used for many years to help treat cancers such as prostate cancer and breast cancer, but it is not currently used in melanoma. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Melanoma and Skin Cancer Trials Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors is being studied. Conditions: Colorectal Liver Metastases, Colorectal Adenocarcinoma, Unresectable Malignant Neoplasm • Eligibility: Inclusion Criteria (Sythesis: 10;10;10;100): * ≥ 18 and \<70 years * Performance status, ECOG 0-1 * Histologically proved adenocarcinoma in colon or rectum. * BRAF wild-type CRC on…. Goal: MELODIC trial is an prospective, multicenter, non-randomized, open-label, parallel trial, aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation (LT) in unresecable CRC liver-only metastases, compared with a matched cohort of patients bearing the same tumor characteristics, and treated with chemotherapy. Synthesis of Inclusion parameters: "10;10;10;100" Phase/Status/Sponsor: Unknown phase; UNKNOWN; Azienda Ospedaliera di Padova.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma is being studied. Conditions: Melanoma, Metastatic Melanoma • Eligibility: Inclusion Criteria: * Patients with histologically confirmed metastatic melanoma * Patients must have recovered from all side effects of their most recent systemic or local treatment for metastatic…. Goal: Anti PD-1 monoclonal antibodies (nivolumab and pembrolizumab) alone or in association with antiCTLA4 (Ipilimumab) are established as indisputable treatment of metastatic melanoma, with unprecedented overall survival, and are indicated for first-line treatment including patients with BRAF mutation. Given their high molecular weight, their penetration in the brain sanctuary is uncertain and relies on disruption of the Blood Brain Barrier (BBB) which occurs occasionally. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Assistance Publique - Hôpitaux de Paris.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy is being studied. Conditions: Melanoma (Skin) • Eligibility: Inclusion Criteria: * Major Patients, * patients with melanoma (stage IV) with cutaneous metastases, * seronegative HIV, HBV, HCV, HTLV1. Exclusion Criteria: * Absence of cutaneous metastasis or…. Goal: The choice of treatment of patients with metastatic melanoma depends on the status of B-RAF of the tumor: in the absence of mutation, treatment with immunotherapy (currently anti-PD1) is proposed in the first line; When B-RAF is mutated, treatment with targeted therapies is retained: B-RAF and MEK inhibitors are prescribed in combination (vemurafenib + cobimetinib or dabrafenib + trametinib). Patient response rates for targeted therapies range from 50 to 60%, and the occurrence of sometimes severe side effects is not predictable. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Centre Hospitalier Universitaire, Amiens.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests ZW25 (zanidatamab) added to standard first-line chemotherapy in people with HER2-expressing gastrointestinal cancers that are unresectable or metastatic, specifically gastroesophageal adenocarcinoma, biliary tract cancer, or colorectal cancer. The study has two parts: Part 1 checks safety and tolerability and helps establish a recommended dose for the combination, and Part 2 evaluates the anti-tumor activity. Eligible participants have HER2-expressing tumors, are unresectable or metastatic, and have good performance status with adequate organ and heart function; colorectal cancer participants must have wild-type RAS/BRAF, with additional biomarker criteria by part. Key exclusions include prior HER2-targeted therapy, recent systemic cancer treatment (with limited exceptions), untreated brain metastases, significant cardiac disease, QTc prolongation, active infections, or uncontrolled HIV/HBV/HCV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Unresectable stage III or stage IV melanoma which is histologically confirmed at the treating institution with KIT mutation(s) not known…. Goal: The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma is being studied. Conditions: Metastatic Melanoma • Eligibility: Inclusion Criteria: * Signed and dated informed consent before any trial-related activities. * Male or female, between 18-75 years of age (both included). * Pathologically confirmed previously treated…. Goal: This is an open-label, phase 1, first-in-human (FIH), dose-escalation, multicenter, multinational trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy and in association with T-cell therapy with TILs in metastatic melanoma patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; TILT Biotherapeutics Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Be willing and able to provide written informed consent for the trial. * Be ≥ 18 years of age on day of signing informed consent.…. Goal: This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: * Pembrolizumab * AMG386 Phase/Status/Sponsor: Unknown phase; COMPLETED; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study is being studied. Conditions: Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV • Eligibility: Inclusion Criteria: 1. Signed Written Informed Consent: patients must be willing and able to give written informed consent, that have to be given before starting of screening procedure.…. Goal: Title: Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic melanoma: a randomized "proof-of-principle" phase II study. Study Design: Randomized selection design, proof of principle study Study Duration: 36 months Number of Subjects: 24 evaluable patients Diagnosis and Main Inclusion Criteria: Patients with non resectable stage III or stage IV malignant melanoma carrying at least 2 measurable lesions, any line after 1st line Vemurafenib in patients carrying BRAF mutation-positive melanoma and/or ≥ 2nd line Ipilimumab. Phase/Status/Sponsor: Unknown phase; COMPLETED; Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention is being studied. Conditions: Metastatic Melanoma • Eligibility: Inclusion Criteria: 1. Participant must be willing to provide a baseline stool sample. 2. Histologically-confirmed Stage IV cutaneous melanoma or Stage III cutaneous, acral or mucosal melanoma that…. Goal: This study is designed to evaluate the safety and tolerability of treatment with oral microbiome study intervention (SER-401) or matching placebo in combination with anti-programmed cell death 1 (anti-PD-1) therapy (nivolumab) in participants with unresectable or metastatic melanoma. The study also intends to assess clinical outcomes, the impact of microbiome study intervention administration on the microbiome profile, and its association with clinical and immunological outcomes. Phase/Status/Sponsor: Unknown phase; COMPLETED; Parker Institute for Cancer Immunotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: * Histologically confirmed unresectable or metastatic melanoma * At least 1 PD-1 targeted immunotherapy and BRAF inhibition in case of BRAF mutated melanoma * Resectable tumor…. Goal: This study is to investigate safety and feasibility of a combination therapy of a tumor infiltrating lymphocytes (TIL) transfer with anti-programmed cell death protein (PD)-1 therapy in patients with metastatic melanoma that failed immunotherapy.Tumor-infiltrating lymphocytes will be expanded from resected melanoma samples from the patient and expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose Interleukin (IL)-2 and nivolumab anti-PD-1 treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Basel, Switzerland.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed primary colorectal cancer * Metastatic disease * Tumor must be confirmed to be K-Ras wild type (i.e., No K-Ras mutation found) by means…. Goal: RATIONALE: Brivanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Phase/Status/Sponsor: Unknown phase; COMPLETED; NCIC Clinical Trials Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer is being studied. Conditions: Malignant Neoplasms of Digestive Organs, Colorectal Cancer, Colon Cancer • Eligibility: Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed metastatic colorectal cancer. 2. Patients must have measurable disease per RECIST v1.1 criteria. 3. Patients must have had…. Goal: The goal of this clinical research study is to learn if durvalumab and trametinib can help to control microsatellite stable (MSS) colorectal cancer. The safety of these drugs will also be studied. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery is being studied. Conditions: Recurrent Melanoma • Eligibility: Inclusion Criteria: * Written informed consent in accordance with federal, local, and institutional guidelines * Patients with unresectable melanoma * Patients must have received a biologic therapy (e.g.…. Goal: This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing. Phase/Status/Sponsor: Unknown phase; COMPLETED; Kari Kendra.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma is being studied. Conditions: Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV • Eligibility: Inclusion Criteria: * Histologically confirmed unresectable stage III or stage IV malignant melanoma, with accessible cutaneous lesions * Must have measurable disease greater than 3 mm * At…. Goal: Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected). These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-7 business days for any delayed adverse events. Phase/Status/Sponsor: Unknown phase; COMPLETED; TuHURA Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Study of PDR001 in Patients With Advanced Malignancies is being studied. Conditions: Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer +2 • Eligibility: Inclusion Criteria: * Written informed consent must have been obtained prior to any screening procedures * Phase I part: Patients with advanced/metastatic solid tumors, with measurable or non-measurable…. Goal: The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent to adult patients with solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma is being studied. Conditions: Stage IIIC Melanoma, Stage IV Melanoma • Eligibility: Inclusion Criteria Participants may be entered in the study only if they meet all of the following criteria. 1. Male or female participants greater than or equal to18…. Goal: The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules. Phase/Status/Sponsor: Unknown phase; COMPLETED; Eisai Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: 1. Patients with histologically documented diagnosis of advanced stage IV or unresectable stage III mucosal or cutaneous melanoma are eligible. 2. They must have recurrent melanoma…. Goal: The goal of this clinical research study is to learn if the combination of ipilimumab and ABI-007 (abraxane) can help to control metastatic melanoma. The safety of this drug combination will also be studied. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: * Registration to CALGB 9581 or 89803 * Samples present within the CALGB Pathology Coordinating Office (PCO) or at the institutions providing treatment that are sufficient…. Goal: This research trial studies tissue samples from patients with stage II colon cancer treated on Cancer and Leukemia Group B (CALGB)-9581 or CALGB-90903. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Alliance for Clinical Trials in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer is being studied. Conditions: Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8 +2 • Eligibility: Inclusion Criteria: * Pathologically confirmed metastatic or unresectable cholangiocarcinoma or gallbladder carcinoma (GBC), having received at least 1 prior line of systemic therapy, and received no more than…. Goal: This randomized phase II trial studies how well atezolizumab with or without cobimetinib works in treating patients with bile duct cancer that has spread to other places in the body (metastatic) and cannot be removed by surgery (unresectable) or gallbladder cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes is being studied. Conditions: Metastatic Melanoma • Eligibility: Inclusion Criteria: * Subject of both sexes at least 18 years of age * Patient with advanced melanoma unresectable (stage IIIc) or metastatic (stage IV) * Patient for…. Goal: Recent progresses have been made in the treatment of metastatic melanoma, nevertheless improved patient survival is still limited because of primary resistance and relapses. It is therefore important to continue to understand the molecular mechanisms involved in melanoma development and progression to improve the management of patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; Centre Hospitalier Universitaire de Nice.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: 1. Subjects must have the ability to understand and willingness to sign a written informed consent document. 2. Part I dose escalation: Have histologically advanced or…. Goal: This is a phase I/II, multi-center, open-label study of YH003 in combination with Toripalimab (anti-PD-1 mAb). The study is comprised of a dose escalation part (Part I) exploring escalating doses of YH003 in combination with fixed dose toripalimab in subjects with advanced solid tumors (Part I), followed by an expansion part (Part II) with three expansion cohorts. Phase/Status/Sponsor: Unknown phase; COMPLETED; Eucure (Beijing) Biopharma Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain is being studied. Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm +2 • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed progressive brain metastases from melanoma or recurrent/progressive malignant glioma (glioblastoma, anaplastic glioma), for which standard curative or palliative measures, with…. Goal: This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting worse. STAT3 inhibitor WP1066 may stop the growth of tumor cells and modulate the immune system. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery is being studied. Conditions: Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 +2 • Eligibility: Inclusion Criteria: * Histologic or cytologic proof of surgically unresectable stage IV malignant melanoma - including that of uveal and mucosal origin * Note: biopsy can be of…. Goal: This randomized phase II trial studies how well nab-paclitaxel and bevacizumab or ipilimumab works as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Phase/Status/Sponsor: Unknown phase; COMPLETED; Academic and Community Cancer Research United.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma is being studied. Conditions: Mucosal Melanoma, Recurrent Melanoma, Recurrent Uveal Melanoma +8 • Eligibility: Inclusion Criteria: * Patients must have malignant melanoma validated by histology or cytology; patients may have had primary cutaneous, mucosal, or ocular melanoma or metastasis from an unknown…. Goal: This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; Fred Hutchinson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Cancer, Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Evaluable or measurable disease per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of ≥12 weeks…. Goal: The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage. Phase/Status/Sponsor: Unknown phase; COMPLETED; Genentech, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: * Participants in the advanced melanoma cohort * Participants included in the cohort by Flatiron criteria of: cutaneous melanoma with pathologic stages III or IV, either…. Goal: The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy Phase/Status/Sponsor: Unknown phase; COMPLETED; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma is being studied. Conditions: Metastatic NRAS Melanoma • Eligibility: Inclusion Criteria: 1. Histologically confirmed metastatic or locally advanced unresectable malignant melanoma with an activating NRAS mutation. 2. Available archival tissue, or if not, the patient is willing…. Goal: Patients with metastatic Neuroblastoma RAS (NRAS) melanoma are currently treated with first line immune checkpoint inhibitors (nivolumab, pembrolizumab). Thus far, no targeted therapy has been approved in NRAS mutated melanoma as a second line treatment, because although the use of a MEK inhibitor (binimetinib) alone was superior to the gold standard chemotherapy (dacarbazine) in a phase 3 trial, the progression free survival gain was very modest. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hospices Civils de Lyon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of SEA-CD40 Given With Other Drugs in Cancers is being studied. Conditions: Melanoma, Carcinoma, Non-Small- Cell Lung • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed unresectable malignancy defined as one of the following: * Cohort 1: Relapsed and/or refractory metastatic melanoma * Uveal/ocular melanoma is excluded…. Goal: This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. Phase/Status/Sponsor: Unknown phase; COMPLETED; Seagen Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) is being studied. Conditions: Glioblastoma • Eligibility: * INCLUSION CRITERIA: Pre-Surgery (Step 1) Inclusion: * Magnetic resonance imaging (MRI) findings consistent with a suspected glioblastoma (GBM) or a histologically confirmed newly diagnosed GBM that has…. Goal: Background: Glioblastoma (GBM) refers to a specific kind of brain cancer called glioblastoma. The standard treatment for GBM is radiation plus temozolomide, an oral chemotherapy drug. Phase/Status/Sponsor: Unknown phase; TERMINATED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors is being studied. Conditions: Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma +6 • Eligibility: Key Inclusion Criteria: * Have a histologically or pathologically documented, locally-advanced or metastatic solid tumor for which standard curative measures do not exist or are no longer effective…. Goal: To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01). Phase/Status/Sponsor: Unknown phase; TERMINATED; Turnstone Biologics, Corp..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy is being studied. Conditions: Metastatic Melanoma, Advanced Melanoma • Eligibility: Inclusion Criteria: 1. Participants must have a histologically or cytologically confirmed advanced/metastatic melanoma by pathology report. Participants with cutaneous, mucosal, acral and unknown primaries will be allowed. 2.…. Goal: This is a first-in-human, multi-center, multi-cohort, open-label, phase Ib/II study of XmAb22841 (CTLA-4 X LAG3) administered in combination with XmAb23104 (PD1 X ICOS) in participants with a histologically or cytologically confirmed diagnosis of an advanced/metastatic melanoma. XmAb22841 (CTLA-4 X LAG3) is a bi-specific antibody targeting two different T cell membrane proteins responsible for regulation of T cell activity. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: * Is of the Chinese descent, was born in China, and has a Chinese home address. * Has histologically confirmed diagnosis of locally advanced (unresectable Stage…. Goal: The purpose of this study is to determine the safety, tolerability, and objective response rate (ORR) of pembrolizumab (MK-3475) in Chinese participants with locally advanced or metastatic melanoma, with disease progression following first line chemotherapy or targeted therapy. ORR will be based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Phase/Status/Sponsor: Unknown phase; COMPLETED; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Signed informed consent form and willingness to comply with study requirements. * Part 1 (Dose-escalation): Adult subject ≤ 75 years old with confirmed advanced solid…. Goal: This is a study to evaluate the safety and tolerability of the study drug HBM4003, and to determine the maximum tolerated dose and/or recommended Phase 2 study dose of HBM4003. The study will also look at the anti-tumor activity of HBM4003.The study consists of 2 parts. Phase/Status/Sponsor: Unknown phase; COMPLETED; Harbour BioMed US, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients is being studied. Conditions: Radiation Dermatitis • Eligibility: Inclusion Criteria: 1. Female subjects diagnosed with stage Tis, T0-T3, N0-N2, M0 Breast Cancer; 2. Subject is ≥18 years at the time of signing the informed consent form…. Goal: The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically administered in breast cancer patients who developed radiation dermatitis. Subjects enrolled to part 1 will be enrolled to receive the study treatment (open label treatment) for 28 days and will be followed up for 2 months after the completion of study treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Lutris Pharma Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases is being studied. Conditions: Melanoma, Non-Small Cell Lung Cancer, Brain Metastases • Eligibility: Inclusion Criteria: 1. Biopsy proven metastatic melanoma or NSCLC as follows: 1. Patients with metastatic melanoma must have untreated brain metastases including: * At least one cerebral metastasis…. Goal: The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Yale University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma is being studied. Conditions: Metastatic Melanoma • Eligibility: Inclusion Criteria: * Patients must be HLA-A2+ and have histologically confirmed melanoma that is metastatic (Stage IV) or unresectable Stage IIIB/C and for which standard curative or palliative…. Goal: Current therapeutic approaches available for patients with advanced-stage melanoma remain inadequate, and existing approaches including those involving immunotherapy with cytokines and/or targeted strategies have resulted in disappointingly low rates of durable and complete responses. Correcting immune dysfunction in advanced-stage melanoma patients using tyrosine-kinase inhibitor (TKI) such as dasatinib is proposed to relicense the patient's immune system to respond optimally to specific immunization. Phase/Status/Sponsor: Unknown phase; COMPLETED; Walter J. Storkus.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors is being studied. Conditions: Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC) +2 • Eligibility: Inclusion Criteria: General Inclusion Criteria: * Part A: Patient must have histologically or cytologically confirmed advanced and/or metastatic solid tumor malignancies for which standard curative or palliative measures…. Goal: This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent lomvastomig (RO7121661), an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. The study consists of 2 parts: Dose Escalation (Part A) and Expansion (Parts B1, B2, B3, B4, and B5). Phase/Status/Sponsor: Unknown phase; COMPLETED; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma is being studied. Conditions: NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: * Male or female patients ≥18 years of age. For Japan only: written consent is necessary both from the patient and his/her legal representative if he/she…. Goal: The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR. Phase/Status/Sponsor: Unknown phase; TERMINATED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Neoplasms • Eligibility: Inclusion Criteria: * Metastatic colorectal cancer, histologically proven (on primary tumour and/or metastases) * Unresectable and non-pretreated metastases * BRAF wild-type * Patient considered able to receive 3…. Goal: The intensity of tumour response appears to be correlated with the feasibility and the duration of a therapeutic pause or of a reduced maintenance therapy maintained until progression in patients initially controlled by so-called "induction" chemotherapy. Bevacizumab combined with cytotoxic chemotherapy (5-FU, irinotecan and/or oxaliplatin) has shown that it is possible to improve the tumour response rate and patient prognosis in 1st and 2nd lines. Phase/Status/Sponsor: Unknown phase; TERMINATED; Federation Francophone de Cancerologie Digestive.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

RTX-224 Monotherapy in Patients With Solid Tumors is being studied. Conditions: Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma +2 • Eligibility: Inclusion Criteria: * Signed written informed consent obtained prior to study procedures Patients ≥18 years with an ECOG of 0 or 1 * R/R, or locally advanced, unresectable,…. Goal: This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Rubius Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. is being studied. Conditions: Melanoma, Thyroid Cancer, Colorectal Cancer +4 • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Measurable disease by RECIST 1.1 criteria (solid tumors) * ECOG performance status of 0-2 * Life expectancy ≥ 3 months…. Goal: The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered PLX8394 in patients with advanced solid tumors. An additional objective is to identify a Recommended Phase 2 (RP2D) for further evaluation in the Extension Cohorts (Phase IIa portion). Phase/Status/Sponsor: Unknown phase; TERMINATED; Fore Biotherapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.